SecBot SecBot

VTGN

Vistagen Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001411685 Biotech & Drug Discovery
$0.1800 +0.00 (+0.00%)
Nov 16 4:00 PM ET · prev $0.1800
Market cap
$7.9M
Nano cap
Median target
$1.00
+456% · range $1.00–1.00
1 year
−95.9%
from $4.42 · Nov 17
30 days
−10.0%
from $0.2000
52-week range
$0.1600–4.90
−96% from high · low Nov 6
Avg volume 20D
761.6K
shares / day
Short interest
2.49M
≈5.6% of shares · +0.6%
Days to cover
3.4
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
19
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 0 bullish · 8 neutral oldest → newest, height = score
Avg score ·High conf. 3/9

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 2 added (0 new), 3 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.365 → −$0.365 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.6% to 2.49M shares. 3.4 days to cover, ≈5.6% of shares.

  • TrendDOWNTREND

    19% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED1,494,279$459.9K
JANE STREET GROUP, LLCDOUBLED532,276$163.8K
GROUP ONE TRADING LLCTRIM208,748$64.3K
MORGAN STANLEYTRIM134$42.00
JPMORGAN CHASE & CONEAR_EXIT16$5.00
ROYAL BANK OF CANADANEAR_EXIT500Not reported
RENAISSANCE TECHNOLOGIES LLCDOUBLED730,500$165.1K
GROUP ONE TRADING LLCDOUBLED304,385$68.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Dec 2025
12-month targets · 2 analysts

Price is below the lowest target. Median implies +456%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Dec 17, 2025William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Dec 17, 2025Maxim Group
DOWNGRADE
DOWNGRADEHold
Dec 17, 2025Jefferies
DOWNGRADE
DOWNGRADEHold
Dec 7, 2023Jefferies
UPGRADE
UPGRADEBuy
Nov 14, 2023Stifel
INITIATE
INITIATEBuy
Sep 5, 2023Maxim Group
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jul 29, 2026
Williamson Douglas J
Director
Jul 29, 2026
AWARD40,826 sh
Jun 30, 2026
Singh Shawn
President and CEO
Jun 30, 2026
AWARD$7.1K
Jun 30, 2026
Tressler Nick B.
Chief Financial Officer
Jun 30, 2026
AWARD$2.2K
Jun 30, 2026
Adler Reid G.
Chief Legal Officer
Jun 30, 2026
AWARD$7.1K
May 18, 2026
Angelov Angel S
Chief Medical Officer
May 18, 2026
AWARD150,000 sh
Apr 7, 2026
Adler Reid G.
Chief Legal Officer
Apr 7, 2026
AWARD18,753 sh
Apr 7, 2026
Prince Joshua S.
Chief Operating Officer
Apr 7, 2026
AWARD56,248 sh
Apr 7, 2026
Cote Elissa S.
Chief Corp Development Officer
Apr 7, 2026
AWARD75,000 sh

Earnings setup

Estimates
−$0.36
EPS estimate, this quarter
0%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.36-$0.37–-$0.36-1.4%$250.0K
Next Q-$0.36-$0.37–-$0.35-2.9%$250.0K
Current FY-$1.48-$1.50–-$1.45-1.7%$1.7M
Next FY-$1.54-$1.54–-$1.54+0.0%$0.00

Short side

FINRA· Oct 30, 2026
2,488,148
shares short
+0.6%
vs prior settlement
3.4
days to cover
≈5.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Vistagen reported a narrower net loss of $10.7M for Q2 FY2027 (vs. $19.4M a year ago), with EPS of -$0.24 beating the…
PRESS-RELEASE · Impact 5/10
Nov 13, 2026 Earnings
Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update
Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder fo
Nov 9, 2026 SEC
Vistagen announced FDA feedback from a Type C meeting for its lead candidate fasedienol in social anxiety disorder…
8-K · Impact 4/10
Nov 9, 2026 Press
Vistagen announced constructive FDA feedback from a Type C meeting on fasedienol for social anxiety disorder…
Impact 4/10
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · DOUBLED
1,494,279 shares ($459.9K)
Sep 30, 2026 Inst.
JANE STREET GROUP, LLC · DOUBLED
532,276 shares ($163.8K)
Sep 24, 2026 Press
Vistagen presented positive exploratory data at Psych Congress 2026 showing a potential efficacy signal for fasedienol…
Impact 4/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

19 filings · 2 press releases · 1 bullish · 3 bearish · 15 neutral
All VTGN filing & press-release reports (21)